NEW YORK, Aug. 7 – Gene Logic spinoff Metrigenix announced on Tuesday its first deal, saying it would work with Neuralstem to co-develop low-density oligonucleotide microarrays designed to study gene expression in the central nervous system.

Metrigenix will provide its Flow-thru Chip technology, while privately held Neuralstem, a developer of stem-cell technology for the human central nervous system, will contribute the content.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.